SPI-1005 for the Treatment of Patients With Meniere's Disease

Status Completed

Clinical Trial Summary

This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.

Clinical Trial Description

Study participants will be randomized to SPI-1005 or placebo in this double-blind study to evaluate both safety and efficacy of the investigational treatment. Participants, aged 18-75 years, with probable or definite Meniere's disease will undergo baseline testing to assess severity of sensorineural hearing loss, tinnitus and vertigo. During the study, and 28 days after completion of treatment, participants will be evaluated for safety (adverse events, physical examinations, vital signs and clinical laboratory testing (CBC,serum chemistry). Trough plasma levels of ebselen and its major metabolite will be determined using liquid chromatography-mass spectrometry (LCMS) at specified visits. Additionally, plasma will be analyzed for selenium at the corresponding visits. The effect of SPI-1005 on hearing and balance will be evaluated. Tinnitus (TFI) and vertigo (VSS) will be evaluated at baseline, during and study treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03325790
Study type	Interventional
Source	Sound Pharmaceuticals, Incorporated
Contact
Status	Completed
Phase	Phase 2
Start date	September 28, 2017
Completion date	April 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06001593` - Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation	Phase 1/Phase 2
Completed	`NCT02612337` - Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Phase 3
Completed	`NCT02265393` - A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom	Phase 2
Completed	`NCT02309099` - Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach	N/A
Completed	`NCT01412177` - OTO-104 for the Treatment of Meniere's Disease	Phase 2
Terminated	`NCT02717442` - Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Phase 3
Completed	`NCT01084525` - OTO-104 for Meniere's Disease	Phase 1
Terminated	`NCT02530931` - Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease	Phase 4
Terminated	`NCT02740387` - Open Label Study of OTO-104 in Subjects With Meniere's Disease	Phase 2
Completed	`NCT02158585` - Study of Lamotrigine to Treat Ménière's Disease	Phase 2
Completed	`NCT00145483` - Sildenafil For Meniere's Disease	Phase 4
Suspended	`NCT04026516` - CAVA: Dizziness Trial	N/A
Recruiting	`NCT03587701` - Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease	Phase 2
Completed	`NCT02080312` - Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent	N/A
Completed	`NCT01454726` - Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease	Phase 3
Recruiting	`NCT01099046` - Stress Management Therapy for Meniere's Disease	N/A
Completed	`NCT00160238` - Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy	Phase 4
Terminated	`NCT02706730` - A 6-Month Extension Study of OTO-104 in Meniere's Disease	Phase 3
Completed	`NCT02718846` - Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets	Phase 4
Completed	`NCT02603081` - Study to Evaluate SPI-1005 in Adults With Meniere's Disease	Phase 1/Phase 2